DexCom, Inc. vs Johnson & Johnson
DXCM vs JNJ — side-by-side comparison from reported financials. DXCM leads 4, JNJ leads 5 of 9 comparable metrics.
DexCom, Inc.
DXCM · Healthcare
$84.11-0.36%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | DXCM | JNJ |
|---|---|---|
| Price | $84.11 | $261.79 |
| Market cap | $31.7B | $631B |
| Revenue (TTM) | $4.97B | $97.9B |
| Revenue growth | +17.0% | +5.6% |
| Net margin | 20.1% | 21.5% |
| Free cash flow | $1.41B | $22.2B |
| Net cash (debt) | ($479M) | ($27.8B) |
| 1-year price return | +23.5% | +37.0% |
| P/E | 31.7 | 29.9 |
| P/E vs own history (cheap-side %) | 93% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 36% | 26% |
| Altman Z-score | 6.78 | — |
| CV checks passed | 10 of 10 | 10 of 10 |
| Employees | 11,100 | 140,800 |
Full résumé-style profiles: DXCM CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.